Opioid Rotation and Equianalgesia in Renal Impairment
A 60-year-old woman with metastatic breast cancer and bone metastases has been on oral morphine 30 mg every 4 hours (180 mg/day) plus morphine 10 mg q2h as needed, using about 4 breakthrough doses daily. She now has progressive renal impairment: creatinine 2.8 mg/dL, eGFR ~22 mL/min/1.73 m². She reports increasing sedation, myoclonus, and 'twitching' despite adequate pain control. The team wants to rotate to oral hydromorphone using a 5:1 morphine-to-hydromorphone conversion and keep the same total daily dose. She also takes gabapentin and dexamethasone.
1. Explain why this patient is showing sedation and myoclonus, and critique the proposed rotation plan.
Read the worked answer
Morphine is metabolized to morphine-6-glucuronide (M6G, analgesic) and morphine-3-glucuronide (M3G, neuroexcitatory). Both are renally cleared. With eGFR ~22, M6G and M3G accumulate, producing sedation (M6G) and myoclonus/hyperalgesia/allodynia (M3G) - the classic opioid neurotoxicity syndrome of renal failure. This is not opioid tolerance or disease progression. Critique of the plan:
- Rotating to hydromorphone is reasonable (its metabolites are less problematic), but hydromorphone also has renally cleared metabolites and can accumulate; dose should be reduced, not simply equianalgesic.
- The 5:1 oral morphine:oral hydromorphone ratio is a rough population estimate; equianalgesic tables vary (some use 5:1, others 7.5:1) and do not account for incomplete cross-tolerance.
- Keeping the 'same total daily dose' ignores both incomplete cross-tolerance and renal accumulation - this risks over-sedation.
- The breakthrough doses (4 × 10 mg = 40 mg) must be added to the baseline (180 mg) to compute total daily morphine = 220 mg/day, then converted, then reduced.
2. Propose a concrete rotation and monitoring plan, including how to handle breakthrough pain and the co-analgesics.
Read the worked answer
Step 1 - total daily morphine: 180 mg scheduled + ~40 mg breakthrough = 220 mg/day. Step 2 - convert: 220 ÷ 5 = 44 mg/day oral hydromorphone. Step 3 - reduce for incomplete cross-tolerance: reduce by 25–50% given renal impairment and neurotoxicity → ~22–33 mg/day, e.g., hydromorphone 4 mg PO q4h (24 mg/day) or 8 mg q8h extended-release if appropriate. Step 4 - breakthrough: use ~10–15% of total daily dose per dose, e.g., hydromorphone 2–4 mg PO q2–4h PRN; reassess. Step 5 - monitoring: pain score, sedation (POSS), respiratory rate, myoclonus resolution, and renal function. Expect neurotoxicity to improve as M3G/M6G clear. Co-analgesics: continue gabapentin (renally dosed - reduce given eGFR 22) and dexamethasone for bone pain; these are opioid-sparing and appropriate. Exam point: in renal failure with neurotoxicity, rotate off morphine, reduce the equianalgesic dose for cross-tolerance and renal accumulation, and titrate - never apply a table ratio at face value.